A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of DWC202404 and DWC202314 Combination Therapy in Patients with Essential Hypertension Inadequately Controlled on DWC202404 Monotherapy
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
192
\- 2 tablet, Oral, Once a day
\- 2 tablet, Oral, Once a day
Hanyang University Medical Center
Seoul, South Korea
Change of MSSBP (Mean Sitting Systolic Blood Pressure) based on baseline
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.